{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:39:26Z","timestamp":1791819566415,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Research Program of Chongqing Municipal Education Commission","award":["KJQN202300118"],"award-info":[{"award-number":["KJQN202300118"]}]},{"name":"Science and Technology Research Program of Chongqing Municipal Education Commission","award":["KJZD-K202000104"],"award-info":[{"award-number":["KJZD-K202000104"]}]},{"name":"Chongqing Science and Health Joint Medical Research Project","award":["2022MSXM004"],"award-info":[{"award-number":["2022MSXM004"]}]},{"name":"Chongqing Science and Health Joint Medical Research Project","award":["2021MSXM085"],"award-info":[{"award-number":["2021MSXM085"]}]},{"name":"Chongqing Research Institute Performance Incentive Guide Special Project, Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JF-0167-05"],"award-info":[{"award-number":["KC2021-JF-0167-05"]}]},{"name":"Talent Program of Chongqing","award":["CQYC20200303137-cstc2021ycjh-bgzxm0193"],"award-info":[{"award-number":["CQYC20200303137-cstc2021ycjh-bgzxm0193"]}]},{"name":"Chongqing Municipal Health and Health Commission","award":["2019NLTS005"],"award-info":[{"award-number":["2019NLTS005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2\u2009+\u2009breast cancer (BrCa) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 120 plasma samples from 40 patients with HER2\u2009+\u2009BrCa were prospectively collected at three treatment times of neoadjuvant therapy (NAT) with TCbHP regimen. Serum metabolites were analyzed based on LC-MS and GC-MS data. Random forest was used to establish predictive models based on pre-therapeutic differentially expressed metabolites. Time series analysis was used to obtain potential monitors for treatment response. Transcriptome analysis was performed in nine available pre\u2011therapeutic specimens of core needle biopsies. Integrated analyses of metabolomics and transcriptomics were also performed in these nine patients. qRT-PCR was used to detect altered genes in trastuzumab-sensitive and trastuzumab-resistant cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one patients achieved pCR, and 19 patients achieved non-pCR. There were significant differences in plasma metabolic profiles before and during treatment. A total of 100 differential metabolites were identified between pCR patients and non-pCR patients at baseline; these metabolites were markedly enriched in 40 metabolic pathways. The area under the curve (AUC) values for discriminating the pCR and non-PCR groups from the NAT of the single potential metabolite [sophorose, N-(2-acetamido) iminodiacetic acid, taurine and 6-hydroxy-2-aminohexanoic acid] or combined panel of these metabolites were greater than 0.910. Eighteen metabolites exhibited potential for monitoring efficacy. Several validated genes might be associated with trastuzumab resistance. Thirty-nine altered pathways were found to be abnormally expressed at both the transcriptional and metabolic levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum-metabolomics could be used as a powerful tool for exploring informative biomarkers for predicting or monitoring treatment efficacy. Metabolomics integrated with transcriptomics analysis could assist in obtaining new insights into biochemical pathophysiology and might facilitate the development of new treatment targets for insensitive patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-024-01813-w","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:03:36Z","timestamp":1712905416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2\u2009+\u2009breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Ningning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhong","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"3","key":"1813_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10071","key":"1813_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","volume":"389","author":"O Ginsburg","year":"2017","unstructured":"Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, et al. The global burden of women\u2019s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847\u201360.","journal-title":"Lancet"},{"issue":"19","key":"1813_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","volume":"32","author":"SH Giordano","year":"2014","unstructured":"Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078\u201399.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1813_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: a review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"2","key":"1813_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100\u20137.","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"1813_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16.","journal-title":"Biomark Res"},{"issue":"26","key":"1813_CR7","doi-asserted-by":"publisher","first-page":"39809","DOI":"10.18632\/oncotarget.9489","volume":"7","author":"G Miolo","year":"2016","unstructured":"Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S, Lombardi D, Rizzolio F, Giordano A, Corona G. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016;7(26):39809\u201322.","journal-title":"Oncotarget"},{"issue":"11","key":"1813_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"6","key":"1813_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"L Gianni","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15(6):640\u20137.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1813_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrclinonc.2016.1","volume":"13","author":"F Penault-Llorca","year":"2016","unstructured":"Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol. 2016;13(8):487\u2013503.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1813_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","volume":"2","author":"KR Broglio","year":"2016","unstructured":"Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive breast Cancer with Long-Term outcomes: a Meta-analysis. JAMA Oncol. 2016;2(6):751\u201360.","journal-title":"JAMA Oncol"},{"key":"1813_CR12","unstructured":"NCCN. Clinical practice guidelines in oncology: breast cancer. Version 4.2021-Aprial 28,2021."},{"key":"1813_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/tbcr-22-21","volume":"3","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, et al. : Chinese society of clinical oncology (CSCO) breast cancer guidelines 2022. Transl Breast Cancer Res. 2022;3:13.","journal-title":"Transl Breast Cancer Res"},{"issue":"1","key":"1813_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1813_CR15","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, et al. Pertuzumab plus Trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384.","journal-title":"Ann Oncol"},{"issue":"3","key":"1813_CR16","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","volume":"6","author":"Z Shao","year":"2020","unstructured":"Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, et al. Efficacy, Safety, and tolerability of Pertuzumab, Trastuzumab, and Docetaxel for patients with early or locally Advanced ERBB2-Positive breast Cancer in Asia: the PEONY phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(3):e193692.","journal-title":"JAMA Oncol"},{"issue":"18","key":"1813_CR17","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.3390\/cancers14184543","volume":"14","author":"M Gamez-Chiachio","year":"2022","unstructured":"Gamez-Chiachio M, Sarrio D, Moreno-Bueno G. Novel therapies and strategies to overcome resistance to Anti-HER2-Targeted drugs. Cancers (Basel). 2022;14(18):4543.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1813_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Martinez-Reyes","year":"2021","unstructured":"Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1813_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/cells8020089","volume":"8","author":"N Gandhi","year":"2019","unstructured":"Gandhi N, Das GM. Metabolic reprogramming in breast Cancer and its therapeutic implications. Cells. 2019;8(2):89.","journal-title":"Cells"},{"issue":"1","key":"1813_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41598-017-01924-9","volume":"7","author":"NI Hadi","year":"2017","unstructured":"Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S, Musharraf SG. Serum metabolomic profiles for breast Cancer diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry. Sci Rep. 2017;7(1):1715.","journal-title":"Sci Rep"},{"issue":"6","key":"1813_CR21","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/1078-0432.CCR-16-1153","volume":"23","author":"CD Hart","year":"2017","unstructured":"Hart CD, Vignoli A, Tenori L, Uy GL, Van To T, Adebamowo C, Hossain SM, Biganzoli L, Risi E, Love RR, et al. Serum metabolomic profiles identify ER-Positive early breast Cancer patients at increased risk of Disease recurrence in a Multicenter Population. Clin Cancer Res. 2017;23(6):1422\u201331.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1813_CR22","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1007\/s00216-015-8484-x","volume":"407","author":"L Yang","year":"2015","unstructured":"Yang L, Cui X, Zhang N, Li M, Bai Y, Han X, Shi Y, Liu H. Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers. Anal Bioanal Chem. 2015;407(17):5065\u201377.","journal-title":"Anal Bioanal Chem"},{"issue":"21","key":"1813_CR23","doi-asserted-by":"publisher","first-page":"8309","DOI":"10.1158\/0008-5472.CAN-10-1319","volume":"70","author":"VM Asiago","year":"2010","unstructured":"Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010;70(21):8309\u201318.","journal-title":"Cancer Res"},{"issue":"1","key":"1813_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41598-019-57068-5","volume":"10","author":"L Li","year":"2020","unstructured":"Li L, Zheng X, Zhou Q, Villanueva N, Nian W, Liu X, Huan T. Metabolomics-based Discovery of Molecular signatures for Triple negative breast Cancer in Asian Female Population. Sci Rep. 2020;10(1):370.","journal-title":"Sci Rep"},{"key":"1813_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ctrv.2018.04.012","volume":"67","author":"A McCartney","year":"2018","unstructured":"McCartney A, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, Di Leo A. Metabolomics in breast cancer: a decade in review. Cancer Treat Rev. 2018;67:88\u201396.","journal-title":"Cancer Treat Rev"},{"key":"1813_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40170-016-0152-x","volume":"4","author":"TH Haukaas","year":"2016","unstructured":"Haukaas TH, Euceda LR, Giskeodegard GF, Lamichhane S, Krohn M, Jernstrom S, Aure MR, Lingjaerde OC, Schlichting E, Garred O, et al. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab. 2016;4:12.","journal-title":"Cancer Metab"},{"issue":"14","key":"1813_CR27","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/1878-0261.13216","volume":"16","author":"C Diaz","year":"2022","unstructured":"Diaz C, Gonzalez-Olmedo C, Diaz-Beltran L, Camacho J, Mena Garcia P, Martin-Blazquez A, Fernandez-Navarro M, Ortega-Granados AL, Galvez-Montosa F, Marchal JA, et al. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach. Mol Oncol. 2022;16(14):2658\u201371.","journal-title":"Mol Oncol"},{"issue":"10","key":"1813_CR28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s11427-013-4557-2","volume":"56","author":"Z Dong","year":"2013","unstructured":"Dong Z, Chen Y. Transcriptomics: advances and approaches. Sci China Life Sci. 2013;56(10):960\u20137.","journal-title":"Sci China Life Sci"},{"issue":"5","key":"1813_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg.2018.4","volume":"19","author":"KJ Karczewski","year":"2018","unstructured":"Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299\u2013310.","journal-title":"Nat Rev Genet"},{"issue":"20","key":"1813_CR30","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105\u201322.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1813_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320\u20137.","journal-title":"Breast"},{"issue":"1","key":"1813_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1039\/C4MB00414K","volume":"11","author":"MN Triba","year":"2015","unstructured":"Triba MN, Le Moyec L, Amathieu R, Goossens C, Bouchemal N, Nahon P, Rutledge DN, Savarin P. PLS\/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol Biosyst. 2015;11(1):13\u20139.","journal-title":"Mol Biosyst"},{"issue":"1\u20132","key":"1813_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijpharm.2017.01.052","volume":"520","author":"AFT Silva","year":"2017","unstructured":"Silva AFT, Sarraguca MC, Ribeiro PR, Santos AO, De Beer T, Lopes JA. Statistical process control of cocrystallization processes: a comparison between OPLS and PLS. Int J Pharm. 2017;520(1\u20132):29\u201338.","journal-title":"Int J Pharm"},{"issue":"2","key":"1813_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/2213235X04666160613122429","volume":"4","author":"B Worley","year":"2016","unstructured":"Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. Curr Metabolomics. 2016;4(2):97\u2013103.","journal-title":"Curr Metabolomics"},{"key":"1813_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF02135323","volume":"19","author":"JB Harborne","year":"1963","unstructured":"Harborne JB. Flavonoid sophorosides. Experientia. 1963;19:7\u20138.","journal-title":"Experientia"},{"issue":"4","key":"1813_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2621.1966.tb01905.x","volume":"31","author":"EH Sugisawa Hirqshi","year":"1966","unstructured":"Sugisawa Hirqshi EH. The thermal degradation of sugars I. Thermal polymerization of glucose. J Food Sci. 1966;31(4):561.","journal-title":"J Food Sci"},{"key":"1813_CR37","doi-asserted-by":"publisher","first-page":"116787","DOI":"10.1016\/j.bmc.2022.116787","volume":"65","author":"RT Miceli","year":"2022","unstructured":"Miceli RT, Corr DT, Barroso M, Dogra N, Gross RA. Sophorolipids: anti-cancer activities and mechanisms. Bioorg Med Chem. 2022;65:116787.","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"1813_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0378-1097(03)00611-6","volume":"226","author":"GB Schuller-Levis","year":"2003","unstructured":"Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett. 2003;226(2):195\u2013202.","journal-title":"FEMS Microbiol Lett"},{"issue":"Suppl 1","key":"1813_CR39","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1423-0127-17-S1-S6","volume":"17","author":"Y Yamori","year":"2010","unstructured":"Yamori Y, Taguchi T, Hamada A, Kunimasa K, Mori H, Mori M. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010;17(Suppl 1):S6.","journal-title":"J Biomed Sci"},{"key":"1813_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-030-93337-1_11","volume":"1370","author":"N Ma","year":"2022","unstructured":"Ma N, He F, Kawanokuchi J, Wang G, Yamashita T. Taurine and its anticancer functions: in vivo and in Vitro Study. Adv Exp Med Biol. 2022;1370:121\u20138.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1813_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00726-013-1545-6","volume":"46","author":"C Kim","year":"2014","unstructured":"Kim C, Cha YN. Taurine chloramine produced from taurine under inflammation provides anti-inflammatory and cytoprotective effects. Amino Acids. 2014;46(1):89\u2013100.","journal-title":"Amino Acids"},{"issue":"1","key":"1813_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/B:NERE.0000010433.08577.96","volume":"29","author":"IH Lambert","year":"2004","unstructured":"Lambert IH. Regulation of the cellular content of the organic osmolyte taurine in mammalian cells. Neurochem Res. 2004;29(1):27\u201363.","journal-title":"Neurochem Res"},{"issue":"3","key":"1813_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10456-011-9215-3","volume":"14","author":"IM El Agouza","year":"2011","unstructured":"El Agouza IM, Eissa SS, El Houseini MM, El-Nashar DE, Abd El Hameed OM. Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients. Angiogenesis. 2011;14(3):321\u201330.","journal-title":"Angiogenesis"},{"issue":"2","key":"1813_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/CBM-181500","volume":"23","author":"X Wang","year":"2018","unstructured":"Wang X, Zhao X, Chou J, Yu J, Yang T, Liu L, Zhang F. Taurine, glutamic acid and ethylmalonic acid as important metabolites for detecting human breast cancer based on the targeted metabolomics. Cancer Biomark. 2018;23(2):255\u201368.","journal-title":"Cancer Biomark"},{"issue":"6","key":"1813_CR45","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00404-022-06587-0","volume":"306","author":"S Arda Duz","year":"2022","unstructured":"Arda Duz S, Mumcu A, Dogan B, Yilmaz E, Inci Coskun E, Saridogan E, Tuncay G, Karaer A. Metabolomic analysis of endometrial cancer by high-resolution magic angle spinning NMR spectroscopy. Arch Gynecol Obstet. 2022;306(6):2155\u201366.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"1813_CR46","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/1055-9965.EPI-18-0936","volume":"28","author":"CS Amara","year":"2019","unstructured":"Amara CS, Ambati CR, Vantaku V, Badrajee Piyarathna DW, Donepudi SR, Ravi SS, Arnold JM, Putluri V, Chatta G, Guru KA, et al. Serum metabolic profiling identified a distinct metabolic signature in bladder Cancer smokers: a key metabolic enzyme Associated with patient survival. Cancer Epidemiol Biomarkers Prev. 2019;28(4):770\u201381.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1813_CR47","doi-asserted-by":"publisher","first-page":"114711","DOI":"10.1016\/j.jpba.2022.114711","volume":"214","author":"W Chen","year":"2022","unstructured":"Chen W, Li Q, Hou R, Liang H, Zhang Y, Yang Y. An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer. J Pharm Biomed Anal. 2022;214:114711.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1813_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3892\/ijmm.2014.2002","volume":"35","author":"X Zhang","year":"2015","unstructured":"Zhang X, Lu H, Wang Y, Liu C, Zhu W, Zheng S, Wan F. Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria. Int J Mol Med. 2015;35(1):218\u201326.","journal-title":"Int J Mol Med"},{"issue":"12","key":"1813_CR49","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.31557\/APJCP.2021.22.12.4001","volume":"22","author":"T Surarak","year":"2021","unstructured":"Surarak T, Chantree P, Sangpairoj K. Synergistic effects of Taurine and Temozolomide Via Cell Proliferation inhibition and apoptotic induction on U-251 MG Human Glioblastoma cells. Asian Pac J Cancer Prev. 2021;22(12):4001\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"1813_CR50","first-page":"5473","volume":"15","author":"S Tu","year":"2018","unstructured":"Tu S, Zhang XL, Wan HF, Xia YQ, Liu ZQ, Yang XH, Wan FS. Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells. Oncol Lett. 2018;15(4):5473\u201380.","journal-title":"Oncol Lett"},{"issue":"4","key":"1813_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/abbs\/gmu004","volume":"46","author":"X Zhang","year":"2014","unstructured":"Zhang X, Tu S, Wang Y, Xu B, Wan F. Mechanism of taurine-induced apoptosis in human colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2014;46(4):261\u201372.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"1813_CR52","doi-asserted-by":"publisher","first-page":"151978","DOI":"10.1016\/j.acthis.2022.151978","volume":"125","author":"M Okano","year":"2023","unstructured":"Okano M, He F, Ma N, Kobayashi H, Oikawa S, Nishimura K, Tawara I, Murata M. Taurine induces upregulation of p53 and Beclin1 and has antitumor effect in human nasopharyngeal carcinoma cells in vitro and in vivo. Acta Histochem. 2023;125(1):151978.","journal-title":"Acta Histochem"},{"key":"1813_CR53","unstructured":"Centeno D, Farsinejad S, Kochetkova E, Volpari T, Klupczynska-Gabryszak A, Kung D, Polotaye T, Hyde E, Pavlovic T, Alshehri S et al. The Dietary Supplement Taurine Suppresses Ovarian Cancer Growth. bioRxiv 2023."},{"issue":"4","key":"1813_CR54","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00262-022-03308-z","volume":"72","author":"Y Ping","year":"2023","unstructured":"Ping Y, Shan J, Liu Y, Liu F, Wang L, Liu Z, Li J, Yue D, Wang L, Chen X, et al. Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8(+) T cell function. Cancer Immunol Immunother. 2023;72(4):1015\u201327.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1813_CR55","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/metabo12060558","volume":"12","author":"J Zhuang","year":"2022","unstructured":"Zhuang J, Yang X, Zheng Q, Li K, Cai L, Yu H, Lv J, Bai K, Cao Q, Li P, et al. Metabolic profiling of bladder Cancer patients\u2019 serum reveals their sensitivity to Neoadjuvant Chemotherapy. Metabolites. 2022;12(6):558.","journal-title":"Metabolites"},{"issue":"1","key":"1813_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms24010012","volume":"24","author":"HS Chae","year":"2022","unstructured":"Chae HS, Hong ST. Overview of Cancer Metabolism and Signaling Transduction. Int J Mol Sci. 2022;24(1):12.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1813_CR57","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.bbadis.2017.05.012","volume":"1863","author":"TL Wong","year":"2017","unstructured":"Wong TL, Che N, Ma S. Reprogramming of central carbon metabolism in cancer stem cells. Biochim Biophys Acta Mol Basis Dis. 2017;1863(7):1728\u201338.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"9","key":"1813_CR58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/1061186X.2022.2091578","volume":"30","author":"A Modi","year":"2022","unstructured":"Modi A, Roy D, Sharma S, Vishnoi JR, Pareek P, Elhence P, Sharma P, Purohit P. ABC transporters in breast cancer: their roles in multidrug resistance and beyond. J Drug Target. 2022;30(9):927\u201347.","journal-title":"J Drug Target"},{"issue":"1","key":"1813_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bbagen.2018.09.019","volume":"1863","author":"A Domenichini","year":"2019","unstructured":"Domenichini A, Adamska A, Falasca M. ABC transporters as cancer drivers: potential functions in cancer development. Biochim Biophys Acta Gen Subj. 2019;1863(1):52\u201360.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"6","key":"1813_CR60","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2012.02.009","volume":"148","author":"R Chen","year":"2012","unstructured":"Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293\u2013307.","journal-title":"Cell"},{"issue":"4","key":"1813_CR61","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.molonc.2012.05.003","volume":"6","author":"L Tenori","year":"2012","unstructured":"Tenori L, Oakman C, Claudino WM, Bernini P, Cappadona S, Nepi S, Biganzoli L, Arbushites MC, Luchinat C, Bertini I, et al. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol. 2012;6(4):437\u201344.","journal-title":"Mol Oncol"},{"issue":"2","key":"1813_CR62","doi-asserted-by":"publisher","first-page":"e24212","DOI":"10.1002\/jcla.24212","volume":"36","author":"C Mao","year":"2022","unstructured":"Mao C, Wang M, Li L, Tang JH. Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes. J Clin Lab Anal. 2022;36(2):e24212.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"1813_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2012.10.003","volume":"7","author":"S Wei","year":"2013","unstructured":"Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE, et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013;7(3):297\u2013307.","journal-title":"Mol Oncol"},{"issue":"48","key":"1813_CR64","doi-asserted-by":"publisher","first-page":"83570","DOI":"10.18632\/oncotarget.18784","volume":"8","author":"E Jobard","year":"2017","unstructured":"Jobard E, Tredan O, Bachelot T, Vigneron AM, Ait-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Dieras V, Jimenez M, et al. Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget. 2017;8(48):83570\u201384.","journal-title":"Oncotarget"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01813-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:04:27Z","timestamp":1712909067000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01813-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was obtained from all participants and all protocols were approved by Chongqing University Cancer Hospital\u2019s ethics committee (CZLS2022022-A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved the final version for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}